Pfizer

Pfizer’s official timeline states that cousins Charles Pfizer and Charles Erhart founded Charles Pfizer & Company in a red-brick building in Brooklyn in 1849. The company moved its headquarters to 81 Maiden Lane in Manhattan in 1868, built on its fermentation capabilities in the late 1930s, and responded to the U.S. government’s World War II request for penicillin by using deep-tank fermentation. Pfizer says it became the world’s largest penicillin producer in 1944, and that Terramycin became its first U.S. pharmaceutical sold under the Pfizer label in 1950. [1]

Pfizer’s 2025 annual review records $62.6 billion in full-year revenue, compared with $63.6 billion in 2024, and says revenue excluding COVID-19 products grew 6% operationally. Its top three products by 2025 revenue were Eliquis at $7.961 billion, the Prevnar family at $6.494 billion, and the Vyndaqel family at $6.380 billion. These figures show a portfolio spanning medicines and vaccines rather than a company dependent on a single therapeutic area. [2]

The 2025 Form 10-K describes Pfizer’s commercial structure as three operating segments: Biopharma, PC1 and Pfizer Ignite. It also places the principal executive offices at 66 Hudson Boulevard East in New York City and reports that Pfizer Global Supply was responsible for 36 manufacturing plants worldwide at December 31, 2025. Pfizer’s current public materials continue to organize its science and products around areas including oncology, vaccines, and inflammation and immunology, linking the company’s historical manufacturing base to contemporary biopharmaceutical research and supply. [3] [4]